

## SYNGENE INTERNATIONAL LIMITED

CIN : L85110KA1993PLC014937 Website: www.syngeneintl.com

Registered office: Biocon SEZ, Biocon Park, Plot No. 2 &amp; 3, Bommasandra Industrial Area IV Phase, Jigani Link Road, Bommasandra, Bangalore - 560099

## STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2026

(Rs. in million, except per share data)

Sl. No.	Particulars	3 months ended	Preceding	Corresponding 3	Year ended	Previous year
		31 March 2026	3 months ended 31 December 2025	months ended in the previous year 31 March 2025	31 March 2026	ended 31 March 2025
		(Audited) (Refer Note 3)	(Unaudited)	(Audited) (Refer Note 3)	(Audited)	(Audited)
1	<b>Income</b>					
	a) Revenue from operations	9,600	8,344	9,484	34,238	33,733
	b) Other Income	216	145	184	669	705
	<b>Total Income</b>	<b>9,816</b>	<b>8,489</b>	<b>9,668</b>	<b>34,907</b>	<b>34,438</b>
2	<b>Expenses</b>					
	a) Cost of chemicals, reagents and consumables consumed	2,022	1,979	2,128	8,243	8,683
	b) Changes in inventories of finished goods and work-in-progress	98	85	70	74	171
	c) Employee benefits expense	2,485	2,175	2,094	9,045	8,417
	d) Finance costs	65	62	101	260	312
	e) Depreciation and amortisation expense [refer note 9]	953	971	896	3,871	3,673
	f) Other expenses [refer note 10]	1,925	2,024	2,056	8,087	7,273
	g) Foreign exchange fluctuation loss/ (gain), net	227	234	36	643	13
	<b>Total expenses</b>	<b>7,775</b>	<b>7,530</b>	<b>7,381</b>	<b>30,223</b>	<b>28,542</b>
3	<b>Profit before tax and exceptional items (1-2)</b>	<b>2,041</b>	<b>959</b>	<b>2,287</b>	<b>4,684</b>	<b>5,896</b>
4	Exceptional items, net gain/ (loss) [refer note 6 ,11 & 12]	(74)	(658)	-	(732)	320
5	<b>Profit before tax (3+4)</b>	<b>1,967</b>	<b>301</b>	<b>2,287</b>	<b>3,952</b>	<b>6,216</b>
6	<b>Tax expense</b>					
	Current tax [refer note 7]	337	56	413	681	1,197
	Deferred tax	148	80	130	222	339
	<b>Total tax expense</b>	<b>485</b>	<b>136</b>	<b>543</b>	<b>903</b>	<b>1,536</b>
7	<b>Profit for the period / year (5-6)</b>	<b>1,482</b>	<b>165</b>	<b>1,744</b>	<b>3,049</b>	<b>4,680</b>
8	<b>Other comprehensive income</b>					
	(A) (i) Items that will not be reclassified to profit or loss	11	(25)	64	(53)	28
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(3)	6	(19)	13	(9)
	(B) (i) Items that will be reclassified to profit or loss	(1,340)	46	739	(3,027)	(143)
	(ii) Income tax relating to items that will be reclassified to profit or loss	308	(12)	(187)	752	43
	<b>Other comprehensive income for the period / year, net of taxes</b>	<b>(1,024)</b>	<b>15</b>	<b>597</b>	<b>(2,315)</b>	<b>(81)</b>
9	<b>Total comprehensive income for the period / year (7+8)</b>	<b>458</b>	<b>180</b>	<b>2,341</b>	<b>734</b>	<b>4,599</b>
10	Paid-up equity share capital (Face value of Rs.10 each) [refer note 5]	4,029	4,029	4,025	4,029	4,025
11	Reserves excluding revaluation reserves as per balance sheet i.e. 'Other Equity'				43,009	42,364
12	<b>Earnings per share (of Rs.10 each)</b>	(not annualised)	(not annualised)	(not annualised)	(annualised)	(annualised)
	a) Basic	3.68	0.41	4.34	7.58	11.64
	b) Diluted	3.68	0.41	4.33	7.57	11.63
	See accompanying notes to the financial results					

SYNGENE INTERNATIONAL LIMITED

CIN : L85110KA1993PLC014937 Website: www.syngeneintl.com

Registered office: Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area IV Phase, Jigani Link Road, Bommasandra, Bangalore - 560099

STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2026

(Rs. in million, except per share data)

Sl. No.	Particulars	3 months ended 31 March 2026	Preceding 3 months ended 31 December 2025	Corresponding 3 months ended in the previous year 31 March 2025	Year ended 31 March 2026	Previous year ended 31 March 2025
		(Audited) (Refer Note 3)	(Unaudited)	(Audited) (Refer Note 3)	(Audited)	(Audited)
1	<b>Income</b>					
	a) Revenue from operations	10,365	9,171	10,180	37,387	36,424
	b) Other Income	222	154	189	707	718
	<b>Total Income</b>	<b>10,587</b>	<b>9,325</b>	<b>10,369</b>	<b>38,094</b>	<b>37,142</b>
2	<b>Expenses</b>					
	a) Cost of chemicals, reagents and consumables consumed	2,233	2,209	2,281	9,112	9,254
	b) Changes in inventories of finished goods and work-in-progress	98	85	69	74	171
	c) Employee benefits expense	3,008	2,674	2,530	11,049	9,839
	d) Finance costs	121	119	159	488	531
	e) Depreciation and amortisation expense [refer note 9]	1,115	1,137	1,061	4,529	4,326
	f) Other expenses [refer note 10]	1,781	1,879	1,818	7,358	6,723
	g) Foreign exchange fluctuation loss/ (gain), net	211	232	46	609	19
	<b>Total expenses</b>	<b>8,567</b>	<b>8,335</b>	<b>7,964</b>	<b>33,219</b>	<b>30,863</b>
3	<b>Profit before tax and exceptional items (1-2)</b>	<b>2,020</b>	<b>990</b>	<b>2,405</b>	<b>4,875</b>	<b>6,279</b>
4	Exceptional items, net gain/ (loss) [refer note 6,11 & 12]	(60)	(706)	-	(766)	320
5	<b>Profit before tax (3+4)</b>	<b>1,960</b>	<b>284</b>	<b>2,405</b>	<b>4,109</b>	<b>6,599</b>
6	<b>Tax expense</b>					
	Current tax [refer note 7]	356	109	469	870	1,384
	Deferred tax	125	25	103	72	253
	<b>Total tax expense</b>	<b>481</b>	<b>134</b>	<b>572</b>	<b>942</b>	<b>1,637</b>
7	<b>Profit for the period / year (5-6)</b>	<b>1,479</b>	<b>150</b>	<b>1,833</b>	<b>3,167</b>	<b>4,962</b>
8	<b>Other comprehensive income</b>					
	(A) (i) Items that will not be reclassified to profit or loss	13	(25)	68	(63)	29
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(3)	6	(19)	16	(9)
	(B) (i) Items that will be reclassified to profit or loss	(1,180)	104	697	(2,679)	(211)
	(ii) Income tax relating to items that will be reclassified to profit or loss	313	(14)	(192)	766	44
	<b>Other comprehensive income for the period / year, net of taxes</b>	<b>(857)</b>	<b>71</b>	<b>554</b>	<b>(1,960)</b>	<b>(147)</b>
9	<b>Total comprehensive income for the period / year (7+8)</b>	<b>622</b>	<b>221</b>	<b>2,387</b>	<b>1,207</b>	<b>4,815</b>
10	Paid-up equity share capital (Face value of Rs.10 each) [refer note 5]	4,029	4,029	4,025	4,029	4,025
11	Reserves excluding revaluation reserves as per balance sheet i.e. 'Other Equity'				44,362	43,243
12	<b>Earnings per share (of Rs.10 each)</b>	(not annualised)	(not annualised)	(not annualised)	(annualised)	(annualised)
	a) Basic	3.68	0.37	4.56	7.87	12.35
	b) Diluted	3.67	0.37	4.56	7.87	12.34
	See accompanying notes to the financial results					

STANDALONE STATEMENT OF ASSETS AND LIABILITIES		
Particulars	(Rs. in Million)	
	As at 31 March 2026	As at 31 March 2025
	(Audited)	(Audited)
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and equipment [refer note 9]	22,440	19,941
Capital work-in-progress [refer note 8]	5,359	8,754
Right-of-use assets	1,765	1,914
Investment property	315	343
Other intangible assets	350	214
Intangible assets under development	53	47
Financial assets		
(i) Investments	11,189	8,701
(i) Derivative assets	317	1,705
(ii) Other financial assets	2,983	389
Deferred tax assets (net)	842	299
Income tax assets (net)	1,130	1,226
Other non-current assets	123	197
<b>Total non-current assets</b>	<b>46,866</b>	<b>43,730</b>
<b>Current assets</b>		
Inventories	1,369	1,503
Financial assets		
(i) Investments	4,446	5,979
(ii) Trade receivables	4,325	4,694
(iii) Cash and cash equivalents	1,205	2,335
(iv) Bank balances other than (iii) above	6,034	4,190
(v) Derivative assets	69	516
(vi) Other financial assets	304	410
Other current assets	1,010	712
<b>Total current assets</b>	<b>18,762</b>	<b>20,339</b>
<b>Total assets</b>	<b>65,628</b>	<b>64,069</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
Equity share capital	4,029	4,025
Other equity	43,009	42,364
<b>Total equity</b>	<b>47,038</b>	<b>46,389</b>
<b>Liabilities</b>		
<b>Non-current liabilities</b>		
Financial liabilities		
(i) Lease liabilities	1,756	1,785
(ii) Derivative liabilities	488	17
(iii) Other financial liabilities	1	-
Provisions	177	404
Other non-current liabilities	1,979	2,188
<b>Total non-current liabilities</b>	<b>4,401</b>	<b>4,394</b>
<b>Current liabilities</b>		
Financial liabilities		
(i) Borrowings	-	1,025
(ii) Lease liabilities	252	253
(ii) Trade payables		
total outstanding dues of micro and small enterprises	500	295
total outstanding dues of creditors other than micro and small enterprises	2,600	3,170
(iii) Derivative liabilities	1,089	49
(iv) Other financial liabilities	867	630
Provisions	1,005	665
Current tax liabilities (net)	171	40
Other current liabilities	7,705	7,159
<b>Total current liabilities</b>	<b>14,189</b>	<b>13,286</b>
<b>Total equity and liabilities</b>	<b>65,628</b>	<b>64,069</b>

CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES		
Particulars	(Rs. in Million)	
	As at 31 March 2026	As at 31 March 2025
	(Audited)	(Audited)
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and equipment [refer note 9]	25,454	23,226
Capital work-in-progress [refer note 8]	10,404	12,614
Right-of-use assets	3,845	4,192
Investment property	315	343
Other intangible assets	386	256
Intangible assets under development	53	47
Financial assets		
(i) Investments	2,850	362
(ii) Derivative assets	317	1,705
(iii) Other financial assets	3,100	454
Deferred tax assets (net)	1,007	295
Income tax assets (net)	1,267	1,243
Other non-current assets	121	349
<b>Total non-current assets</b>	<b>49,119</b>	<b>45,086</b>
<b>Current assets</b>		
Inventories	1,413	1,555
Financial assets		
(i) Investments	4,561	6,105
(ii) Trade receivables	5,088	5,267
(iii) Cash and cash equivalents	2,286	3,671
(iv) Bank balances other than (iii) above	6,044	4,199
(v) Derivative assets	69	532
(vi) Other financial assets	304	244
Other current assets	1,663	1,300
<b>Total current assets</b>	<b>21,428</b>	<b>22,873</b>
<b>Total assets</b>	<b>70,547</b>	<b>67,959</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
Equity share capital	4,029	4,025
Other equity	44,362	43,243
<b>Total equity</b>	<b>48,391</b>	<b>47,268</b>
<b>Liabilities</b>		
<b>Non-current liabilities</b>		
Financial liabilities		
(i) Lease liabilities	3,985	4,088
(ii) Derivative liabilities	488	18
(iii) Other financial liabilities	1	-
Provisions	180	433
Other non-current liabilities	1,979	2,188
<b>Total non-current liabilities</b>	<b>6,633</b>	<b>6,727</b>
<b>Current liabilities</b>		
Financial liabilities		
(i) Borrowings	94	1,196
(ii) Lease liabilities	505	495
(ii) Trade payables		
total outstanding dues of micro and small enterprises	588	341
total outstanding dues of creditors other than micro and small enterprises	2,887	3,179
(iii) Derivative liabilities	1,145	56
(iv) Other financial liabilities	1,100	704
Provisions	1,144	713
Current tax liabilities (net)	277	84
Other current liabilities	7,783	7,196
<b>Total current liabilities</b>	<b>15,523</b>	<b>13,964</b>
<b>Total equity and liabilities</b>	<b>70,547</b>	<b>67,959</b>

STANDALONE STATEMENT OF CASH FLOWS			
(Rs. in Million)			
Sl. No.	Particulars	Year ended 31 March 2026 (Audited)	Year ended 31 March 2025 (Audited)
<b>1</b>	<b>Cash flows from operating activities</b>		
	Profit for the year	3,049	4,680
	<u>Adjustments to reconcile profit after tax to net cash flows</u>		
	Depreciation and amortisation expense	3,871	3,673
	Gain on remeasurement of lease	-	(32)
	Loss on assets scrapped	28	26
	Provision for doubtful receivables	(53)	57
	Loss on write off of receivables arising from cumulative foreign exchange movements	277	-
	Bad debts written off	2	16
	Provision for doubtful advances to supplier	37	-
	Share based compensation expense	334	302
	Interest expense	260	312
	Unrealised foreign exchange (gain)/loss	58	35
	Net gain on sale of current investments	(90)	(155)
	Interest on income tax refund	(11)	(47)
	Interest income	(568)	(503)
	Provision on inventory obsolescence	131	(23)
	Tax expenses	903	1,536
	<b>Operating profit before working capital changes</b>	<b>8,228</b>	<b>9,877</b>
	<b>Movements in working capital</b>		
	Decrease/ (increase) in inventories	4	861
	Decrease/ (increase) in trade receivables	(202)	(497)
	Decrease/ (increase) in other assets	(1,109)	63
	Increase/ (decrease) in trade payables, other liabilities and provisions	1,831	1,849
	<b>Cash generated from operations</b>	<b>8,752</b>	<b>12,153</b>
	Income taxes paid (net of refunds)	(442)	(1,015)
	<b>Net cash flow generated from operating activities</b>	<b>8,310</b>	<b>11,138</b>
<b>2</b>	<b>Cash flows from investing activities</b>		
	Purchase of property, plant and equipment	(2,638)	(3,693)
	Purchase of intangible assets	(235)	(86)
	Investment in equity shares	(35)	(4,336)
	Investment in bank deposits and inter corporate deposits	(13,828)	(7,965)
	Redemption/ maturity of bank deposits and inter corporate deposits	7,945	8,450
	Interest received	480	498
	Proceeds from sale of current investments	19,198	21,172
	Purchase of current investments	(18,725)	(22,144)
	<b>Net cash flow used in investing activities</b>	<b>(7,838)</b>	<b>(8,104)</b>
<b>3</b>	<b>Cash flows from financing activities</b>		
	Issue of equity shares	4	5
	Proceeds/ (repayments) from long term borrowings	-	(417)
	Proceeds/ (repayments) from short term borrowings, net	(917)	-
	Lease liabilities paid including interest	(268)	(317)
	Dividend paid	(504)	(503)
	Interest paid	(93)	(133)
	<b>Net cash flow used in financing activities</b>	<b>(1,778)</b>	<b>(1,365)</b>
<b>4</b>	<b>Net decrease in cash and cash equivalents (1+2+3)</b>	<b>(1,306)</b>	<b>1,669</b>
5	Effect of exchange difference on cash and cash equivalents held in foreign currency	176	-
6	Cash and cash equivalents at the beginning of the year	2,335	666
<b>7</b>	<b>Cash and cash equivalents at the end of the year (4+5+6)</b>	<b>1,205</b>	<b>2,335</b>

SYNGENE INTERNATIONAL LIMITED

CIN : L85110KA1993PLC014937 Website: www.syngeneintl.com

Registered office: Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area IV Phase, Jigani Link Road, Bommasandra, Bangalore - 560099

CONSOLIDATED STATEMENT OF CASH FLOWS			
		(Rs. in Million)	
Sl. No.	Particulars	Year ended	Year ended
		31 March 2026	31 March 2025
		(Audited)	(Audited)
<b>1</b>	<b>Cash flows from operating activities</b>		
	Profit for the year	3,167	4,962
	<u>Adjustments to reconcile profit after tax to net cash flows</u>		
	Depreciation and amortisation expense	4,529	4,326
	Gain on remeasurement of lease	-	(32)
	Loss on assets scrapped	28	26
	Provision for doubtful receivables	(61)	49
	Bad debts written off	2	30
	Loss on write off of receivables arising from cumulative foreign exchange movements	277	-
	Advances to suppliers written off	37	-
	Share based compensation expense	413	373
	Interest expense	488	531
	Unrealised foreign exchange (gain)/loss	37	37
	Net gain on sale of current investments	(94)	(159)
	Interest income	(602)	(512)
	Interest on income tax refund	(11)	(47)
	Provision on inventory obsolescence	112	88
	Tax expenses	942	1,636
	<b>Operating profit before working capital changes</b>	<b>9,264</b>	<b>11,308</b>
	<b>Movements in working capital</b>		
	Decrease/ (increase) in inventories	30	743
	Decrease/ (increase) in trade receivables	(199)	(939)
	Decrease/ (increase) in other assets	(1,461)	(126)
	Increase/ (decrease) in trade payables, other liabilities and provisions	2,211	1,843
	<b>Cash generated from operations</b>	<b>9,845</b>	<b>12,829</b>
	Income taxes paid (net of refunds)	(693)	(1,153)
	<b>Net cash flow generated from operating activities</b>	<b>9,152</b>	<b>11,676</b>
<b>2</b>	<b>Cash flows from investing activities</b>		
	Purchase of property, plant and equipment	(3,440)	(7,603)
	Purchase of intangible assets	(242)	(98)
	Investment in equity shares	(35)	-
	Investment in bank deposits and inter corporate deposits	(13,828)	(12,099)
	Redemption/ maturity of bank deposits and inter corporate deposits	7,945	12,738
	Interest received	508	503
	Proceeds from sale of current investments	21,222	22,547
	Purchase of current investments	(20,734)	(23,435)
	<b>Net cash flow used in investing activities</b>	<b>(8,604)</b>	<b>(7,447)</b>
<b>3</b>	<b>Cash flows from financing activities</b>		
	Proceeds from issue of equity shares	4	5
	Proceeds/(repayments) from long term borrowings	-	(417)
	Proceeds/ (repayments) from short term borrowings, net	(996)	171
	Lease liabilities paid including interest	(548)	(536)
	Dividend paid	(504)	(503)
	Interest paid on borrowings	(106)	(138)
	<b>Net cash flow used in financing activities</b>	<b>(2,150)</b>	<b>(1,418)</b>
<b>4</b>	<b>Net decrease in cash and cash equivalents (1+2+3)</b>	<b>(1,602)</b>	<b>2,811</b>
<b>5</b>	Effect of exchange difference on cash and cash equivalents held in foreign currency	217	3
<b>6</b>	Cash and cash equivalents at the beginning of the year	3,671	857
<b>7</b>	<b>Cash and cash equivalents at the end of the year (4+5+6)</b>	<b>2,286</b>	<b>3,671</b>

## SYNGENE INTERNATIONAL LIMITED

### Notes :



- 1 The statement of audited standalone and consolidated financial results ("the Statements") of Syngene International Limited ('the Company') for the quarter and year ended 31 March 2026 have been reviewed by the Audit Committee at their meeting held on 28 April 2026 and approved by the Board of Directors of the Company at their meeting held on 29 April 2026. The above Statements have been audited by the statutory auditor of the Company. The reports of the statutory auditor are unqualified. The Statements have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 2 The consolidated financial results include the financial results of the Company - Syngene International Limited (including its employee welfare trust) and the financial results of the following subsidiaries:
  - i. Syngene USA Inc.
  - ii. Syngene Scientific Solutions Limited
  - iii. Syngene Manufacturing Solutions LimitedThe Company and the Subsidiaries are collectively referred to as 'the Group'.
- 3 The standalone and consolidated figures for quarter ended 31 March 2026 and 31 March 2025 are the balancing figures between audited figures in respect of the full financial year and the published unaudited year to date figures upto end of the third quarter of the relevant financial year which are subjected to limited review.
- 4 The Group operates in a single segment of providing Contract Research and Manufacturing Services.
- 5 On 23 April 2025, the Board of Directors of the Company have approved an allotment of 402,439 equity shares of Rs. 10/- (Rs. Ten each) of the Company to Syngene Employees Welfare Trust at face value pursuant to special resolution passed through Postal Ballot on 23 April 2023 to allot fresh equity shares upto 0.55% (22,00,000 shares) of the paid equity capital of the company in tranches for the purpose of implementation of the Syngene International Limited - Restricted Stock Unit Long Term Incentive Plan FY 2023.
- 6 During the quarter ended 30 June 2024, the Company received its final claim of Rs 320 million from the insurance company for the loss of fixed assets in a fire incident on 12 December 2016, and the same has been presented in the financial results under the head 'Exceptional Items' for the year ended 31 March 2025.
- 7 During the quarter ended 31 December 2024, the Company opted for "Vivad se Vishwas Scheme, 2024" which resulted in settlement of pending TDS assessments related to non resident tax deductions. Consequent to this, tax expense under the scheme amounting to Rs. 95 million was recorded under the head "Current tax" during the year 31 March 2025.
- 8 During the quarter ended 31 March 2025, Syngene USA Inc. (wholly-owned subsidiary of the Company) acquired biologics site in the USA fitted with multiple monoclonal antibody (mAbs) manufacturing lines from Emergent Manufacturing Operations Baltimore, LLC (a subsidiary of Emergent BioSolutions Inc.). This acquisition will increase the company's total single-use bioreactor capacity to 50,000L for large molecule discovery, development, and manufacturing services. This acquisition will also increase the options that can be offered to global customers, providing commercial scale biologics manufacturing capabilities across the Group's global network. The transaction was accounted for as an 'asset acquisition' under Ind AS 103 during the year ended 31 March 2025. The costs incurred till 31 March 2025 eligible for capitalization were accumulated as Capital Work in Progress amounting to Rs. 2,981 million (USD 34.89 million). An amount of Rs. 311 million (USD 3.64 million) was capitalized as Land. These amounts include pre-transaction costs of Rs 101 million (USD 1.18 million). During the year ended 31 March 2026, additional pre-operating cost of Rs. 786 million (USD 8.4 million) eligible for capitalisation is being accumulated under capital work in progress.

## SYNGENE INTERNATIONAL LIMITED

- 9 During the quarter ended 30 June 2025, the Company has been granted license for one of the drug substance production line and bonded warehouse license at biologics manufacturing facility, Bangalore, India which was acquired from Stelis Biopharma Limited and was recorded as capital work in progress in earlier years. Consequently, Rs. 3,438 million has been capitalised as property, plant and equipment which has resulted in a higher depreciation of Rs. 70 million and Rs. 247 million during the quarter and period ended 31 March 2026 respectively.
- 10 During the quarter ended 30 September 2025, Rs. 277 million net (Rs. 202 million after tax) was written off as unrecoverable balances in receivables due to cumulative changes in foreign exchange rates.
- 11 On November 21, 2025, the Government of India notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws. The Ministry of Labour & Employment published draft Central Rules and Frequently Asked Questions (FAQs) to enable assessment of the financial impact due to changes in regulations. The Group initially assessed and disclosed the incremental impact of these changes on the basis its existing remuneration structure. Considering the materiality and regulatory-driven, non-recurring nature of this impact, the Group presented such incremental impact under "Exceptional Items" in the standalone and consolidated financial results for the period ended December 31, 2025. The incremental expense consisting of gratuity of Rs. 658 million and Rs. 706 million in the standalone and consolidated financial results respectively primarily arose due to change in wage definition. During the quarter ended 31 March 2026, the management re-assessed the impact of the new labour codes based on the revised remuneration structure. Accordingly, the gratuity obligation was re-measured, resulting in a credit of Rs. 229 million in the standalone financial results and Rs. 244 million in the consolidated financial results for the current quarter. For the year ended 31 March 2026, the net expense recognised under Exceptional Items amounted to Rs. 429 million and Rs. 462 million in the standalone and consolidated financial results, respectively. The Group continues to monitor the finalisation of Central / State Rules and clarifications from the Government on other aspects of the Labour Code and would accordingly take necessary steps for compliance thereof and also provide appropriate accounting effect on the basis of such developments, as needed.
- 12 During the quarter ended 31 March 2026, termination benefits amounting to INR 304 million were extended to employees in accordance with the approved policy. Considering the nature, significance and frequency of these benefits, these are disclosed as "Exceptional items" in the standalone and consolidated financial results.
- 13 **Events after reporting period :**
- a) On 29 April 2026, the Board of Directors of the Company have approved an allotment of 7,29,727 equity shares of Rs. 10/- (Rupees Ten each) of the Company to Syngene Employees Welfare Trust at face value for the purpose of implementation of the Syngene Long Term Incentive Performance Share Plan 2023.
- (b) On 29 April 2026, the Board of Directors recommended a final dividend of Rs. 1.25 per equity share of Rs. 10/-. The proposed dividend is subject to the approval of the shareholders in the Annual General Meeting.

**Place :-** Bangalore  
**Date :-** 29 April 2026

For and on behalf of the Board of Directors of  
Syngene International Limited

KIRAN  Digitally signed  
by KIRAN  
MAZUMDAR  
SHAW  
AR SHAW  Date: 2026.04.29  
15:54:36 +05'30'

Kiran Mazumdar Shaw  
Chairperson